Safety Study of SBRT and Docetaxel for Locally Recurrent or Second Primary Squamous Cell Carcinoma of the Head and Neck

NCT02110992 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

7

Enrollment

OTHER

Sponsor class

Stopped slow accrual

Conditions

Head and Neck Cancer

Interventions

DRUG: Docetaxel
RADIATION: Stereotactic Radiation

Sponsor

University of Cincinnati